OverviewSuggest Edit

Sientra, a medical device company, develops and markets products focusing on the plastic surgery and aesthetics market. Sientra is committed to providing plastic surgeons with intuitive, elegant solutions— as reflected in its innovative round and shaped product lines. It offers breast implants, breast tissue expanders, silicone scar treatment, and additional tissue expanders.
TypePublic
Founded2007
HQGoleta, US
Websitesientra.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Dec 2019)339(+31%)
Job Openings2
Revenue (FY, 2019)$83.7 M(+23%)
Share Price (Nov 2020)$5.2
Cybersecurity ratingCMore

Key People/Management at Sientra

Jeffrey Nugent

Jeffrey Nugent

Chairman and Chief Executive Officer
Oliver Bennett

Oliver Bennett

General Counsel and VP of Compliance & Legal
Deborah Bettencourt

Deborah Bettencourt

Vice President, Human Resources & Corporate Administration
Dan Carlisle

Dan Carlisle

Vice President, Innovation & Product Development, Breast Products
Kirk Gunhus

Kirk Gunhus

Senior Vice President of Worldwide Sales
Jeff Jones

Jeff Jones

Vice President, Operations
Show more

Sientra Office Locations

Sientra has an office in Goleta
Goleta, US (HQ)
420 S Fairview Ave #200
Show all (1)

Sientra Financials and Metrics

Sientra Revenue

Embed Graph
View revenue for all periods
Sientra's revenue was reported to be $83.70 m in FY, 2019
USD

Revenue (Q2, 2020)

12.4m

Gross profit (Q2, 2020)

6.9m

Gross profit margin (Q2, 2020), %

55.4%

Net income (Q2, 2020)

(34.3m)

EBIT (Q2, 2020)

(12.3m)

Market capitalization (12-Nov-2020)

263.4m

Closing stock price (12-Nov-2020)

5.2

Cash (30-Jun-2020)

71.8m

EV

254.9m
Sientra's current market capitalization is $263.4 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

44.7m38.1m20.7m36.5m68.1m83.7m

Revenue growth, %

(15%)(46%)

Cost of goods sold

11.5m10.7m6.9m14.2m26.8m33.0m

Gross profit

33.2m27.5m13.9m22.4m41.3m50.7m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

10.7m12.4m14.2m9.9m1.5m6.2m6.5m7.5m8.2m9.8m14.7m17.6m16.9m17.6m20.5m22.4m16.9m12.4m

Cost of goods sold

2.8m3.2m3.9m2.9m760.0k1.7m1.8m2.3m2.6m3.5m6.1m6.7m6.4m6.5m7.8m9.8m6.8m5.6m

Gross profit

7.8m9.2m10.3m7.0m711.0k4.5m4.7m5.2m5.5m6.3m8.6m10.9m10.5m11.1m12.7m12.7m10.1m6.9m

Gross profit Margin, %

73%74%72%70%48%72%72%69%68%65%58%62%62%63%62%56%60%55%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

96.7m112.8m67.2m26.6m86.9m87.6m

Accounts Receivable

7.4m8.2m11.8m6.6m22.5m27.5m

Prepaid Expenses

1.5m2.6m2.5m

Inventories

1.8m1.5m1.9m20.9m24.1m39.6m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(5.8m)(41.2m)(40.2m)(64.0m)(82.6m)(106.8m)

Depreciation and Amortization

275.0k318.0k1.2m3.0m3.3m3.5m

Inventories

1.4m(898.0k)2.4m527.0k(4.2m)(10.9m)

Accounts Payable

(2.3m)1.5m(564.0k)1.3m8.5m(2.2m)
USDQ3, 2014

Debt/Equity

-0.2 x

Debt/Assets

0.4 x

Financial Leverage

-0.5 x
Show all financial metrics

Sientra Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

SecurityScorecard logo

Sientra Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Sientra Online and Social Media Presence

Embed Graph

Sientra News and Updates

Sientra Appoints Ron Menezes as President and Chief Executive Officer

Jeffrey Nugent, Current Chairman and Chief Executive Officer, Announces His Retirement

Sientra Announces Preliminary Unaudited 4Q19 Net Sales and Appointment of Caroline Van Hove to Board of Directors

Anticipates total fourth quarter net sales of $23.2 million, growth of 22% year over year

Sientra Announces Acquisition of the Independently Operated OPUS® Breast Implant Manufacturing Operation from Lubrizol Life Science

Vertical integration critical next step in advancing Sientra’s strategic objectives

United States Breast Implant Market Size, Trends & Forecast 2025 Featuring Mentor, Allergan Natrelle, Sientra, Ideal Implant Incorporated, Arion Laboratories, GC Anesthetics, Establishment Labs

DUBLIN, Sept. 26, 2019 /PRNewswire/ -- The "US Breast Implant Market Size, Trends & Forecast 2025" report has been added to ResearchAndMarkets.com's offering. "US Breast Implant Market Size, Trends & Forecast 2025" Report Highlights: US Breast Implant Market Opportunity: > US$ 1 Billion..…

Global Breast Implants (Augmentation & Reconstruction) Markets, 2017-2018 & 2019-2023 with Profiles of Allergan,GC Aesthetics, Johnson & Johnson, Sientra

DUBLIN, Aug. 14, 2019 /PRNewswire/ -- The "Global Breast Implants Market with Focus on Breast Augmentation & Breast Reconstruction: Size, Trends and Forecasts (2019-2023)" report has been added to ResearchAndMarkets.com's offering. The global breast implants market has increased...

Sientra to Report Second Quarter 2019 Financial Results on August 8, 2019

SANTA BARBARA, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Sientra, Inc. (Nasdaq: SIEN), a medical aesthetics company, announced today that it will release financial results for the second quarter 2019 after the close of trading on Thursday, August 8, 2019. Sientra will host a conference call to dis…
Show more

Sientra Frequently Asked Questions

  • When was Sientra founded?

    Sientra was founded in 2007.

  • Who are Sientra key executives?

    Sientra's key executives are Jeffrey Nugent, Oliver Bennett and Deborah Bettencourt.

  • How many employees does Sientra have?

    Sientra has 339 employees.

  • What is Sientra revenue?

    Latest Sientra annual revenue is $83.7 m.

  • What is Sientra revenue per employee?

    Latest Sientra revenue per employee is $246.9 k.

  • Who are Sientra competitors?

    Competitors of Sientra include GC Aesthetics, Vapotherm and Vesiflo.

  • Where is Sientra headquarters?

    Sientra headquarters is located at 420 S Fairview Ave #200, Goleta.

  • Where are Sientra offices?

    Sientra has an office in Goleta.

  • How many offices does Sientra have?

    Sientra has 1 office.